


WHAT IS CLAIMED IS:

1. Compounds of Formula I:



5 wherein:


 R_1 is hydroxyl, alkoxy of 1-4 carbons, or $-\text{O}(\text{CH}_2)_n\text{X}$; n is an integer of 1-3; X is CONHR_6 or CO_2R_6 ; R_2 is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or

10 acyl of 1-4 carbons;

 R_3 , R_4 and R_5 are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF_3 , OCF_3 , SO_2NHR_6 , NR_6R_7 or CO_2R_6 ; R_6 , and R_7 are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl15 where the aryl group is substituted with R_2 ;

or a pharmaceutically acceptable salt thereof.

2. Compounds of Formula II:



20

wherein:

 R_1 is hydroxyl, alkoxy of 1-4 carbons, or $-\text{O}(\text{CH}_2)_n\text{X}$; n is an integer of 1-3;

X is CONHR₆ or CO₂R₆;

R₂ is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;


R₃, R₄ and R₅ are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4

5 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF₃, OCF₃, SO₂NHR₆, NR₆R₇ or CO₂R₆;

R₆, and R₇ are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with R₂; or a pharmaceutically acceptable salt thereof.

10

3. Compounds of Formula III:



wherein:

15 R₁ is hydroxyl, alkoxy of 1-4 carbons, or -O(CH₂)_nCO₂R₅;

n is an integer of 1-3;

R₂ is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;

R₃, R₄, are each, independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons,

20 alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF₃, OCF₃, SO₂NHR₅, NR₅R₆, or CO₂R₅;

R₅, R₆ are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where aryl group is substituted with R₂;

or a pharmaceutically acceptable salt thereof.

25

4. The compound of claim 1, which is 6-Methoxy-5-([4-(trifluoromethoxy)benzyl]amino)methyl)-2-naphthoic acid.

5. The compound of claim 1, which is 5-[(4-Fluorobenzyl)amino]methyl)-6-methoxy-2-naphthoic acid.


6. The compound of claim 1, which is 5-({[4-(Aminosulfonyl)benzyl]amino}methyl)-6-methoxy-2-naphthoic acid.

5

7. The compound of claim 1, which is 5-({[4-(Dimethylamino)benzyl]amino}methyl)-6-methoxy-2-naphthoic acid.

10 8. The compound of claim 1, which is 6-(Carboxymethoxy)-5-({[4-(trifluoromethoxy)benzyl]amino}methyl)-2-naphthoic acid.

9. A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof which comprises administering to 15 said mammal, a therapeutically effective amount of a compound of Formula I:



wherein:

R₁ is hydroxyl, alkoxy of 1-4 carbons or -O(CH₂)_nX;

20 n is an integer of 1-3;


X is CONHR₆, or CO₂R₆;

R₂ is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons or acyl of 1-4 carbons;

R₃, R₄ and R₅ are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF₃, OCF₃, SO₂NHR₆, 25 NR₆R₇ or CO₂R₆;

R_6 , and R_7 are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with R_2 ;
or a pharmaceutically acceptable salt thereof.

5 10. A method of treating or inhibiting type II diabetes in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of compound of Formula I:



wherein:

R1 is hydroxyl, alkoxy of 1-4 carbons or $-\text{O}(\text{CH}_2)_n\text{X}$;

10 n is an integer of 1-3;

X is CONHR_6 or CO_2R_6 ;


R_2 is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;

R_3 , R_4 and R_5 are each, independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF_3 , OCF_3 , SO_2NHR_6 , NR_6R_7 or CO_2R_6 ;

R_6 , and R_7 are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with R_2 ;
or a pharmaceutically acceptable salt thereof.

20

11. A method of modulating glucose levels in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I:



wherein:

R_1 is hydroxyl, alkoxy of 1-4 carbons, or $-\text{O}(\text{CH}_2)_n\text{X}$;

n is an integer of 1-3;

X is CONHR_6 or CO_2R_6 ;


5 R_2 is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons or acyl of 1-4 carbons;

R_3 , R_4 and R_5 are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF_3 , OCF_3 , SO_2NHR_6 , NR_6R_7 or rCO_2R_6 ;

10 R_6 , and R_7 are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with R_2 ;

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition which comprises a compound of Formula I:



15

wherein:

R_1 is hydroxyl, alkoxy of 1-4 carbons, or $-\text{O}(\text{CH}_2)_n\text{X}$;

n is an integer of 1-3;

X is CONHR_6 , or CO_2R_6 ;

20 R_2 is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;

R_3 , R_4 , and R_5 are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons, CF_3 , OCF_3 , SO_2NHR_6 , NR_6R_7 , or CO_2R_6 ;

25 R_6 , and R_7 are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with R_2 ;

or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier.